Drug Profile


Alternative Names: TA-1702

Latest Information Update: 25 May 2010

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer GlaxoSmithKline
  • Class
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 25 May 2010 Discontinued - Phase-I for Overactive bladder in USA (unspecified route)
  • 01 Oct 2007 Tanabe Seiyaku Co. Ltd has merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation
  • 30 Sep 2007 Suspended - Phase-I for Overactive bladder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top